Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology
Language English Country United States Media print-electronic
Document type Journal Article, Multicenter Study
PubMed
32004645
DOI
10.1016/j.jaad.2020.01.049
PII: S0190-9622(20)30133-X
Knihovny.cz E-resources
- Keywords
- autoimmune bullous diseases, biochip, immunofluorescence, pemphigoid, pemphigus,
- MeSH
- Autoimmune Diseases blood diagnosis MeSH
- Pemphigoid, Bullous blood diagnosis immunology MeSH
- Child MeSH
- Adult MeSH
- Fluorescent Antibody Technique, Indirect methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Pemphigus blood diagnosis immunology MeSH
- Prospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
BACKGROUND: The current standard in the serologic diagnosis of autoimmune bullous diseases (AIBD) is a multistep procedure sequentially applying different assays. In contrast, the BIOCHIP Mosaic technology combines multiple substrates for parallel analysis by indirect immunofluorescence. METHODS: Sera from 749 consecutive, prospectively recruited patients with direct immunofluorescence-positive AIBD from 13 international study centers were analyzed independently and blinded by using (1) a BIOCHIP Mosaic including primate esophagus, salt-split skin, rat bladder, monkey liver, monkey liver with serosa, recombinant BP180 NC16A, and gliadin GAF3X, as well as HEK293 cells expressing recombinant desmoglein 1, desmoglein 3, type VII collagen, and BP230 C-terminus and (2) the conventional multistep approach of the Department of Dermatology, University of Lübeck. RESULTS: In 731 of 749 sera (97.6%), specific autoantibodies could be detected with the BIOCHIP Mosaic, similar to the conventional procedure (725 cases, 96.8%). The Cohen κ for both serologic approaches ranged from 0.84 to 1.00. In 6.5% of sera, differences between the 2 approaches occurred and were mainly attributed to autoantigen fragments not present on the BIOCHIP Mosaic. LIMITATIONS: Laminin 332 and laminin γ1 are not represented on the BIOCHIP Mosaic. CONCLUSIONS: The BIOCHIP Mosaic is a standardized time- and serum-saving approach that further facilitates the serologic diagnosis of AIBD.
Department of Dermatology and Immunodermatology Medical University of Warsaw Warsaw Poland
Department of Dermatology and Venereology Sofia University of Medicine Sofia Bulgaria
Department of Dermatology Beijing University 1st Hospital Beijing China
Department of Dermatology Faculty of Medicine Akdeniz University Antalya Turkey
Department of Dermatology Poznan University of Medical Sciences Poznan Poland
Department of Dermatology School of Medicine University of Belgrade Belgrade Serbia
Department of Dermatology St Anna University Hospital Brno Czech Republic
Department of Dermatology Tel Aviv Sourasky Medical Center Tel Aviv Israel
Department of Dermatology University of Lübeck Lübeck Germany
Institute of Experimental Immunology EUROIMMUN AG Lübeck Germany
Lübeck Institute of Experimental Dermatology Lübeck Germany
Molecular and Cell Biology Laboratory IDI IRCCS Rome Italy
St George Hospital University of New South Wales School of Medicine Sydney Australia
University Institute of Clinical Chemistry and Center of Laboratory Medicine Bern Switzerland
References provided by Crossref.org
